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1  | BACKGROUND
Maternal obesity is associated with neonatal1-4 and childhood adi-
posity, and childhood obesity2,5 is not only associated with a higher 
chance of obesity, but also premature death and disability in adult-
hood.5 While maternal insulin resistance and fasting glucose have a 
positive association with neonatal adiposity,6-13 the role of maternal 
triglycerides and non-esterified fatty acids on neonatal adiposity 
remains controversial.6-8,11 It is unclear whether such associations 
are causal, in the causal pathway or a consequence of the metabolic 
pathways involved.
Shapiro et al6 reported that HOMA-IR, glucose, but not tri-
glycerides and non-esterified fatty acids at 24-32 weeks of gesta-
tion mediated the association between maternal pre-pregnancy 
body mass index (BMI) and neonatal adiposity. Although this study6 
provided relevant insights regarding the possible underlying mech-
anisms in the relationship between maternal metabolic profile and 
neonatal adiposity, some aspects still require further evaluation. 
First, it is crucial that the entire pregnancy period is taken into ac-
count. Fetal development depends on the maternal metabolic profile 
throughout the whole pregnancy period,6-13 illustrated by the fact 
that obese women or women who develop gestational diabetes have 
larger fetuses already by 20 weeks of gestation.14,15 Second, there 
is evidence that neonatal girls might be more insulin resistant than 
boys,16,17 and mechanisms underlying the relationship between ma-
ternal metabolism and neonatal adiposity might differ depending on 
the neonatal sex.18
The aim of this investigation was to evaluate the direct and in-
direct associations between insulin resistance during pregnancy 
and neonatal adiposity, as measured by sum of skinfolds. In addi-
tion, the direct and indirect associations between fasting glucose, 
triglycerides, non-esterified fatty acids, and neonatal adiposity 
were also assessed. This is a novel approach because it assesses 
the complexity of the relationships among different maternal health 
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parameters throughout pregnancy and its impact on neonatal adi-
posity. Although the observational design does not allow to assert 
on causality, it is a valuable approach for generating hypothesis to 
be tested in clinical trials.
2  | METHODS
2.1 | Design and participants
This is a longitudinal, secondary analysis of the DALI study 
which was a multicentre parallel randomised trial conducted in 
nine European countries (Austria, Belgium, Denmark, Ireland, 
Italy, Netherlands, Poland, Spain, and United Kingdom) during 
2012-2015. Pregnant women with a pre-pregnancy body mass 
index (BMI) of ≥29 kg/m2, before 20 weeks of gestation, with 
a singleton pregnancy, and aged ≥18 years were invited to par-
ticipate.19 Exclusions included diagnosis with early gestational 
diabetes mellitus (GDM), pre-existing diabetes, and chronic 
medical conditions. The study was prospectively registered 
as a randomised controlled trial (RCT) on 21 November 2011 
(ISRCTN70595832).
2.2 | Randomisation, masking, and interventions
Using a computerised random number generator, women were ran-
domised to one of the following groups, pre-stratified for site: (a) healthy 
eating; (b) physical activity; (c) healthy eating + physical activity; (d) 
healthy eating + physical activity + vitamin D; (e) healthy eating + physi-
cal activity + placebo; (f) vitamin D; (g) placebo; and (h) control. Staff 
involved with measurements, but not participants, were blinded to the 
intervention. Since methodology has been extensively described else-
where,19 only variables of interest will be detailed in this manuscript.
2.3 | Measurements
2.3.1 | Neonatal adiposity
Triceps, subscapular, supra-iliac, and quadriceps skinfolds were meas-
ured with a Harpenden skinfold calliper, and values summed. Each 
skinfold measurement was repeated once, and if a difference of more 
than 0.2 mm was registered, a third measurement was performed and 
the average of the three was taken. Time between birth and meas-
urements was registered in hours—neonatal age at the measurement.
2.3.2 | Maternal measurements
Maternal height was determined at baseline with a stadiometer 
(SECA 206; SECA, Birmingham United Kingdom). Women were 
weighed on calibrated electronic scales (SECA 888 and 877) at 
baseline (<20 weeks), 24-28 weeks, and at 35-37 weeks of gestation. 
Body mass index (BMI) was calculated as weight in kg divided by the 
square of height in metres.
After fasting for 10 hours, blood was collected in three different 
periods during pregnancy (<20, 24-28, and 35-37 weeks of gestation). 
The procedures were identical in all pregnancy periods. All the sam-
ples were centrifuged and separated aliquots (1000 or 250 μL) placed 
in microrack tubes and stored at −20 or −80°C in the central trial labo-
ratory, prior to analysis, in Graz, Austria. The maternal plasma concen-
trations of fasting glucose, triglycerides, and non-esterified fatty acids 
were quantified. For insulin and leptin, commercially available en-
zyme-linked immunosorbent assays (ELISAs) were used. Insulin resis-
tance was derived from homeostasis model assessment (HOMA-IR).20
2.3.3 | Covariates
Information on possible covariates was collected in the baseline 
questionnaire or from medical files: intervention groups, maternal 
age, gestational age during pregnancy (<20, 24-28 and 35-37 weeks), 
maternal ethnicity (European descent and non-European descent), 
maternal education (low [<high school], medium [completed high 
school] and high [higher education]), smoking status at 35-37 weeks 
of gestation (yes and no), gestational age at birth (weeks of gesta-
tion), and neonatal age (hours).
Synopsis
Study question
How is the synergic relationship of maternal insulin re-
sistance, fasting glucose, triglycerides, and non-esterified 
fatty acids with neonatal adiposity in pregnant women 
with obesity?
What's already known
Maternal insulin resistance and fasting glucose have a 
positive association with neonatal adiposity, and the role 
of maternal triglycerides and non-esterified fatty acids on 
neonatal adiposity remains controversial.
What this study adds
The association between maternal insulin resistance and 
neonatal adiposity differed depending on the infant sex. 
While adiposity in boys was associated directly with ma-
ternal insulin resistance in the beginning of pregnancy, 
adiposity in girls was associated with maternal insulin re-
sistance at 24-28 weeks of gestation via a chain of relation-
ships through fasting glucose, triglycerides, and free fatty 
acids.
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2.4 | Statistical analyses
Prevalence, means, standard deviations (SD), medians, and inter-
quartile ranges (IQR) were used to describe the sample. Descriptive 
mean differences are presented with respective 95% confidence 
intervals.
Structural equation modelling was performed to evaluate the 
direct and indirect associations among maternal HOMA index, glu-
cose, triglycerides, non-esterified fatty acids, and neonatal sum of 
skinfolds. Direct association refers to the association between two 
variables, whereas indirect association refers to the association be-
tween two variables that is mediated via a third variable. All the stan-
dard errors in the analyses were adjusted for the cluster structure 
of the data (individuals nested within site of recruitment). Table 1 
describes the role of each variable in the diagram in detail, including 
the variables of interest and the adjustments. We have more than 
80% statistical power to detect associations with small effect sizes 
(f2 = 0.06) considering the number of neonatal boys (n = 333) and 
girls (n = 324) evaluated, accounting for the number of exposures 
and confounding variables in our analysis. All analyses were per-
formed in STATA version 15 for windows (StataCorp LP).
2.5 | Missing data
We used the maximum likelihood for missing values method, which 
does not exclude a participant in the analysis because of a missing 
value in one of the variables. Thus, we avoided selection bias in our 
analysis.21 Therefore, all the 657 neonates and their mothers in the 
study were included in the main analysis.
2.6 | Ethics approval
We obtained the local ethics committee approvals in all the nine 
countries, in which the study was conducted. Moreover, written in-
formed consent of all women was acquired.
3  | RESULTS
In total, 657 neonates (50.7% boys) and their mothers with obe-
sity were included in the study. On average, the mothers were 32.0 
(±5.4) years of age. Median gestational age at delivery was 39.7 (IQR: 
38.7; 40.9) weeks of gestation. Most mothers perceived themselves 
as European descent (86.4%). Among the mothers, 55.9% reported a 
high educational level and 31.8% a medium educational level. Median 
neonatal age at measurement was 5.0 (IQR: 2.0; 24.0) hours after 
birth. Boys exhibited a lower sum of skinfolds (mean sum of skinfolds 
20.3 mm, 95% CI 19.7, 21.0) compared to girls (mean sum of skinfolds 
21.5 mm, 95% CI 20.8, 22.2). Table 2 presents descriptive data on the 
mothers’ metabolic variables at <20 weeks of gestation according to 
the sex of the fetus.
3.1 | Maternal insulin resistance in relation to 
neonatal adiposity
In boys, maternal HOMA-IR at <20 weeks of gestation was directly 
associated with neonatal sum of skinfolds (β = 0.35 mm, 95% CI 0.01, 
0.70). No other associations of maternal HOMA-IR with neonatal 
sum of skinfolds in boys were found (see Table 3). In girls, maternal 
HOMA-IR was not directly associated with neonatal sum of skin-
folds at any time during pregnancy. However, maternal HOMA-IR 
at 24-28 weeks of gestation was indirectly associated with neonatal 
sum of skinfolds (β = 0.26 mm, 95% CI 0.08, 0.44).
Figure 1 illustrates the indirect association of maternal HOMA-IR 
at 24-28 weeks of gestation with neonatal sum of skinfolds only in 
girls because we did not observe an indirect association between 
maternal HOMA-IR and neonatal sum of skinfolds in boys. Note that 
not all the arrows were drawn for clarity. We only drew the most 
relevant arrows related to the primary and secondary outcomes of 
the present study. For more details regarding all the relationships 
tested in our diagram, see Table 1. The indirect association of ma-
ternal HOMA-IR at 24-28 weeks of gestation with neonatal sum of 
skinfolds indicates that a higher maternal HOMA-IR at 24-28 weeks 
initiates a chain of relationships through maternal fasting glucose, 
triglycerides, and NEFA at 24-28 weeks and HOMA-IR, fasting glu-
cose, triglycerides, and NEFA at 35-37 weeks that culminates in a 
higher neonatal sum of skinfolds (Figure 1). The overall indirect as-
sociation between maternal HOMA-IR at 24-28 weeks and neonatal 
sum of skinfolds was 0.26 mm (95% CI 0.06, 0.36), and the indirect 
association between maternal HOMA-IR at 24-28 weeks and neona-
tal sum of skinfolds only via maternal fasting glucose at 24-28 weeks 
was 0.21 mm (95% CI 0.06, 0.36), indicating that 81.0% of the in-
direct relationship between maternal HOMA-IR at 24-28 weeks 
and neonatal sum of skinfolds was mediated via fasting glucose at 
24-28 weeks.
3.2 | Maternal fasting glucose, 
triglycerides, and non-esterified fatty acids in relation 
to neonatal adiposity
In boys, maternal triglycerides at <20 weeks were indirectly 
and negatively associated with neonatal sum of skinfolds 
(β = −0.49 mm, 95% CI −0.97, −0.01). Moreover, triglycerides at 
24-28 weeks of gestation were directly and negatively associ-
ated with neonatal sum of skinfolds (β = −1.39 mm, 95% CI −2.58, 
−0.21). Maternal fasting glucose and NEFA were not associated 
with neonatal sum of skinfolds in boys at any time during preg-
nancy (Table 4).
In girls, maternal fasting glucose at <20 weeks was inversely and 
directly associated with neonatal sum of skinfolds (β = −2.52 mm, 
95% CI −4.86, −0.19), whereas the indirect association was posi-
tive (β = 1.82 mm, 95% CI 0.85, 2.79). Thus, the total association 
between maternal fasting glucose at <20 weeks and neonatal sum 
of skinfolds was not significant (β = −0.70 95% CI −2.94, 1.54). 
     |  5LIMA et AL.
Maternal fasting glucose at 24-28 weeks was directly and posi-
tively associated with neonatal sum of skinfolds (β = 2.51 mm, 95% 
CI 0.80, 4.23). Maternal NEFA at 35-37 weeks were directly and 
negatively associated with neonatal sum of skinfolds (β=−3.26 mm, 
95% CI −5.91, −0.61). Maternal triglycerides were not associated 
with neonatal sum of skinfolds in girls at any time during pregnancy 
(Table 4).
3.3 | Comment
3.3.1 | Principal findings
The primary aim of this investigation was to evaluate the potential 
pathophysiological pathways underlying the association of mater-
nal insulin resistance with neonatal adiposity in pregnant women 
TA B L E  1   Pathways between all the variables in the analysis
 Outcomes
Exposures
HOMA-IR at 13-20 wk HOMA-Index at 24-28 and 35-37 wk; Glucose at 13-20, 24-28 and 35-37 wk; Triglycerides 
at 13-20, 24-28 and 35-37 wk; Non-esterified fatty acids at 13-20, 24-28 and 35-37 wk; 
Neonatal fatness
HOMA-IR at 24-28 wk HOMA-Index at 35-37 wk; Glucose at 24-28 and 35-37 wk; Triglycerides at 24-28 and 
35-37 wk; Non-esterified fatty acids at 24-28 and 35-37 wk; Neonatal fatness
HOMA-IR at 35-37 wk Glucose at 35-37 wk; Triglycerides at 35-37 wk; Non-esterified fatty acids at 35-37 wk; 
Neonatal fatness
Fasting glucose at 13-20 wk Glucose at 24-28 and 35-37 wk; Neonatal fatness
Fasting glucose at 24-28 wk Glucose at 35-37 wk; Neonatal fatness
Fasting glucose at 35-37 wk Neonatal fatness
Triglycerides at 13-20 wk Triglycerides at 24-28, 35-37 wk; Neonatal fatness
Triglycerides at 24-28 wk Triglycerides at 35-37 wk; Neonatal fatness
Triglycerides at 35-37 wk Neonatal fatness
Non-esterified fatty acids at 13-20 wk Non-esterified fatty acids at 24-28, 35-37 wk; Neonatal fatness
Non-esterified fatty acids at 24-28 wk Non-esterified fatty acids at 35-37 wk; Neonatal fatness
Non-esterified fatty acids at 35-37 wk Neonatal fatness
Confounders
Intervention groups BMI at 13-20, 24-28 and 35-37 wk;
Gestational age HOMA-Index at 13-20, 24-28 and 35-37 wk;
Maternal ethnicity Glucose at 13-20, 24-28 and 35-37 wk;
Maternal education Triglycerides at 13-20, 24-28 and 35-37 wk;
Maternal age Non-esterified fatty acids at 13-20, 24-28 and 35-37 wk;
Smoking status Neonatal fatness
BMI at 13-20 wk BMI at 24-28 and 35-37 wk;
HOMA-Index at 13-20, 24-28 and 35-37 wk;
Glucose at 13-20, 24-28 and 35-37 wk;
Triglycerides at 13-20, 24-28 and 35-37 wk;
Non-esterified fatty acids at 13-20, 24-28 and 35-37 wk;
Neonatal fatness
BMI at 24-28 wk BMI at 35-37 wk;
HOMA-Index at 24-28 and 35-37 wk;
Glucose at 24-28 and 35-37 wk;
Triglycerides at 24-28 and 35-37 wk;
Non-esterified fatty acids at 24-28 and 35-37 wk;
Neonatal fatness
BMI at 35-37 wk HOMA-Index at 35-37 wk;
Glucose at 35-37 wk;
Triglycerides at 35-37 wk;
Non-esterified fatty acids at 35-37 wk;
Neonatal fatness
Neonatal age Neonatal fatness
Gestational age at birth
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with obesity. Since this is a longitudinal study, it is not possible to 
infer causality in our conclusions. Our results showed that the asso-
ciation between maternal insulin resistance and neonatal adiposity 
differed depending on the infant sex. While adiposity in boys was 
associated directly with maternal insulin resistance in the beginning 
of pregnancy, adiposity in girls was associated with maternal insulin 
resistance at 24-28 weeks of gestation via a chain of relationships 
through fasting glucose, triglycerides, and free fatty acids.
3.3.2 | Strengths of the study
Strengths of our study are that we have measures of maternal meta-
bolic parameters at three time points in pregnancy, enabling us to look 
at longitudinal associations. Data were collected in nine European 
countries, increasing the external validity of our findings. Importantly, 
the mechanistic path analysis adds substantial insights on how some 
of the metabolic parameters during pregnancy in women with obesity 
could affect neonatal adiposity, although we cannot assert on causal-
ity and our model should be tested in clinical trials.
3.3.3 | Limitations of the data
Our findings should be interpreted with caution, since women 
were exposed to different interventions that could influence 
our results. However, the analyses were adjusted for the in-
tervention component. Another limitation is the lack of nor-
mal or overweight women in the study; thus, we can only 
generalise our findings to Caucasian obese women. However, 
the prevalence and the increasing rate of obesity in women 
in reproductive age are alarming and so the complication re-
lated to obesity during pregnancy.22,23 Furthermore, more 
direct measures of neonatal adiposity would have been pre-
ferred, such as from air displacement plethysmography, al-
though sum of skinfolds provide valid estimates of adiposity 
in neonates.24,25
3.3.4 | Interpretation
Regarding the pathophysiological pathways on the relationship 
between maternal metabolism and neonatal adiposity, Shapiro 
et al7 observed that 21.0% of the association between mater-
nal pre-pregnancy BMI and neonatal adiposity was mediated by 
HOMA-IR and fasting glucose levels, but not by triglycerides or 
non-esterified fatty acids.7 This is partly in line with our results, al-
though Shapiro et al7 included pregnant women with and without 
obesity whereas we only included pregnant women with obesity. 
We observed that fasting glucose mediated 81.0% of the associa-
tion between maternal HOMA-IR and neonatal adiposity, but only 
in girls.
Maternal variables
<20 wk of gestation
Boys Girls
n Mean (95% CI) n Mean (95% CI)
HOMA-IR ([µU/
mL]*[mmol/L])
327 3.0 (2.7, 3.4) 315 3.3 (2.9, 3.6)
Fasting Glucose 
(mmol/L)
331 4.6 (4.6, 4.6) 320 4.6 (4.6, 4.7)
Triglycerides (mmol/L) 320 1.3 (1.3, 1.4) 307 1.4 (1.3, 1.4)
Non-esterified fatty 
acids (mmol/L)
320 0.6 (0.6, 0.7) 307 0.64 (0.6, 0.7)
BMI (kg/m2) 333 34.4 (34.0, 34.8) 324 34.5 (34.0, 35.0)
TA B L E  2   Mean and 95% confidence 
intervals of the mothers’ anthropometric 
and metabolic variables at <20 wk of 
gestation according to the sex of the fetus
TA B L E  3  Path coefficients of the di-
rect, indirect, and total association be-
tween maternal HOMA-IR and neonatal 
sum of skinfolds
Exposures
Neonatal 
sex
Neonatal sum of skinfolds (mm)
Direct association Indirect association Total association
HOMA-IR 
at < 20 wk
Boys 0.35 (0.01, 0.70) −0.02 (−0.17, 0.14) 0.34 (0.01, 0.66)
Girls 0.20 (−0.02, 0.43) −0.05 (−0.18, 0.08) 0.15 (−0.08, 0.38)
HOMA-IR at 
24-28 wk
Boys −0.43 (−0.88, 0.03) 0.09 (−0.05, 0.22) −0.34 (−0.83, 0.15)
Girls 0.01 (−0.41, 0.41) 0.26 (0.08, 0.44) 0.26 (−0.09, 0.61)
HOMA-IR at 
35-37 wk
Boys 0.05 (−0.12, 0.22) 0.05 (−0.03, 0.14) 0.10 (−0.11, 0.31)
Girls −0.01 (−0.12, 0.10) 0.07 (−0.01, 0.15) 0.06 (−0.05, 0.17)
Note: Indirect association refers to the association between the exposure (maternal HOMA-IR at dif-
ferent periods during pregnancy) and the outcome (neonatal sum of skinfolds) which is mediated by all 
the variables in the pathway (see Table 1 for detailed description).
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F I G U R E  1   Paths in the association 
between maternal HOMA-IR at 24-
28 wk and neonatal sum of skinfolds 
in girls. Fasting glucose, triglycerides, 
and non-esterified fatty acids (NEFA) at 
24-28 wk were directly associated with 
fasting glucose, triglycerides, and NEFA at 
35-37 wk, respectively. SSF refers to the 
neonatal sum of skinfolds (mm). Solid lines 
refer to direct relationships; dashed lines 
refer to indirect relationships
TA B L E  4   Path coefficients of the direct, indirect, and total association between maternal fasting glucose, triglycerides, non-esterified 
fatty acids, and neonatal sum of skinfolds
Exposures, in mmol/l
Gestational age during 
pregnancy
Outcome: Sum of skinfolds (mm)
Boys
Total association Direct association Indirect association
β (95% CI) β (95% CI) β (95% CI)
Fasting glucose <20 wk 0.44 (−1.10, 1.98) −0.31 (−2.06, 1.43) 0.75 (−0.60, 2.11)
24-28 wk 0.68 (−1.36, 2.72) 0.09 (−1.86, 2.04) 0.59 (−0.38, 1.57)
35-37 wk 1.22 (−0.75, 3.19) 1.22 (−0.75, 3.19)  
Triglycerides <20 wk 1.12 (−0.59, 2.84) 1.61 (−0.31, 3.54) −0.49 (−0.97, −0.01)
24-28 wk −0.87 (−1.58, −0.15) −1.39 (−2.58, −0.21) 0.53 (−0.23, 1.28)
35-37 wk 0.78 (−0.26, 1.81) 0.78 (−0.26, 1.81)  
Non-esterified fatty acids <20 wk 1.01(−1.27, 3.28) 1.19 (−0.33, 2.71) −0.18 (−1.92, 1.55)
24-28 wk −1.58 (−5.90, 2.75) −1.77 (−6.17, 2.62) 0.20 (−0.38, 0.77)
35-37 wk 1.32 (−2.56, 5.20) 1.32 (−2.56, 5.20)  
Exposures, in mmol/l
Gestational age during 
pregnancy
Outcome: Sum of skinfolds (mm)
Girls
Total association Direct association Indirect association
β (95% CI) β (95% CI) β (95% CI)
Fasting glucose <20 wk −0.70 (−2.94, 1.54) −2.52 (−4.86, −0.19) 1.82 (0.85, 2.79)
24-28 wk 2.84 (1.38, 4.30) 2.51 (0.80, 4.23) 0.33 (−0.24, 0.90)
35-37 wk 0.71 (−0.49, 1.91) 0.71 (−0.49, 1.91)  
Triglycerides <20 wk 0.80 (−0.30, 1.90) 0.43 (−1.31, 2.17) 0.37 (−0.99, 1.72)
24-28 wk 0.01 (−1.47, 1.50) −0.64 (−2.46, 1.19) 0.65 (−0.44, 1.74)
35-37 wk 0.93 (−0.63, 2.49) 0.93 (−0.63, 2.49)  
Non-esterified fatty acids <20 wk 1.73 (−0.88, 4.34) 1.47 (−0.38, 3.31) 0.26 (−1.07, 1.60)
24-28 wk 2.23 (−1.92, 6.38) 3.02 (−0.99, 7.03) −0.79 (−1.74, 0.16)
35-37 wk −3.26 (−5.91, −0.61) −3.26 (−5.91, −0.61)  
Note: Indirect association refers to the association between the exposure and the outcome (neonatal sum of skinfolds) which is mediated by all the 
variables in the pathway (see Table 1 for detailed description). The empty cells on the indirect relationships between fasting glucose, triglycerides, 
non-esterified fatty acids at 35-37 wk of gestation and neonatal sum of skinfolds are due to the lack of possible indirect relationships to be estimated 
(there are no intermediate variable between these exposures and the outcome).
8  |     LIMA et AL.
The direct association between maternal glucose and neona-
tal adiposity is well established in the literature.6,8-10 Results from 
the Healthy Heart Study6,7 and the Hyperglycemia and Adverse 
Pregnancy Outcome (HAPO) study26 demonstrated the importance 
of maternal glucose levels for neonatal adiposity. In our sample only 
including pregnant women with obesity, we did not observe any re-
lationship between maternal fasting glucose and neonatal adiposity 
in boys. In girls, maternal fasting glucose at 24-28 weeks was associ-
ated with neonatal adiposity. No relationship was observed between 
maternal fasting glucose at <20 weeks or at 35-37 weeks and neo-
natal adiposity. We encourage future investigations to evaluate this 
matter in more depth, with assessment of maternal glucose levels at 
multiple time points during pregnancy.
The importance of triglycerides and non-esterified fatty acids 
levels during pregnancy on neonatal adiposity is not well estab-
lished.6,8,11 When associations are found they are usually posi-
tive.27 In our sample with pregnant women with obesity, maternal 
triglycerides were negatively associated with neonatal adiposity in 
boys at <20 weeks (indirectly) and at 24-28 weeks (directly). In girls, 
maternal non-esterified fatty acids at 35-37 weeks showed a nega-
tive association with neonatal adiposity. Pregnant women with obe-
sity from DALI exposed to motivational sessions on healthy eating 
presented higher levels of NEFA, and higher levels of NEFA were 
also found in the cord blood of the offspring when compared to con-
trols.28 In addition, maternal diet has been shown to influence tri-
glyceride and free fatty acid levels, even after a period of fasting.29 
Whether this influenced the association between lipids and neonatal 
adiposity is unknown. However, there seems to be a complex inter-
action between maternal glycaemia and lipids in their influence on 
fetal growth, since maternal lipids were only associated with fetal 
growth in women with hyperglycaemia but not in those with normal 
glycaemia.30 Whether this is due to differences in insulin resistance 
and therefore maternal lipolysis needs further study.
Sex differences in the associations between maternal metabo-
lism and neonatal adiposity have been reported previously, but are 
inconsistent.16,17,31 Inconsistencies might be due to study popula-
tion (ie women with obesity versus with normal weight, with normal 
glycaemia versus with hyperglycaemia) or due to differences in the 
timing in pregnancy. Theoretically, male and female fetuses seem 
to experience different growth strategies in utero.32,33 It is not well 
established yet, but male embryos tend to have more rapid cell di-
visions compared to females,34 generating a more rapid growth.32,33 
This higher growth rate might explain the higher response to 
changes in nutrient supply reported in male fetuses.32,33 These dif-
ferent growth strategies might result in differences in nutritional 
needs, at different times in pregnancy and our findings support this 
concept. However, more systematic assessment of sex differences 
in the relationship of maternal metabolic parameters with neonatal 
adiposity is needed.
We evaluated the pathophysiological pathway from mater-
nal insulin resistance, through maternal glucose, triglycerides, and 
non-esterified fatty acids to neonatal adiposity in pregnant women 
with obesity. It indicates again the relevance of the early pregnancy 
period for neonatal outcomes in boys and in the middle of pregnancy 
for girls. Although our model explained most of the pathophysiolog-
ical pathways from insulin resistance to neonatal adiposity in girls, 
the pathways in boys were still uncertain. A next step would be to 
investigate the associations of maternal metabolism with cord blood 
parameters, to confirm the Pedersen-Freinkel hypothesis that ma-
ternal glucose and lipids increase fetal insulin levels and thereby in-
crease fetal fat accretion.35
4  | CONCLUSIONS
Maternal insulin resistance in women with obesity was associ-
ated with adiposity in neonates. More specifically, higher insulin 
resistance in the beginning of pregnancy was related to higher 
adiposity in boys, whereas this association in girls was observed 
with insulin resistance in the middle of the pregnancy period. 
Obstetricians, midwives, and health professionals should be 
aware of the deleterious impact of maternal insulin resistance on 
the offspring health and support pregnant women with life style 
changes (nutrition and physical activity) which could lower insulin 
resistance during pregnancy and consecutively benefit neonatal 
body composition.36
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